Low dose decitabine versus best supportive caref in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups - Wijermans, P (Blood, 2008)
et al.